Regeneron Pharmaceuticals financials
$750.51−0.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B |
| Gross profit | $12.24B | $12.23B | $11.30B | $10.61B | $13.63B | $7.38B | $5.79B | $4.73B | $5.48B | $4.56B |
| Gross margin | 85.4% | 86.1% | 86.2% | 87.2% | 84.8% | 86.8% | 88.3% | 91.9% | 93.2% | 93.8% |
| Operating income | $3.57B | $4.04B | $4.04B | $4.74B | $8.95B | $3.58B | $2.21B | $2.53B | $2.08B | $1.33B |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $895.5M |
| Net margin | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 32.3% | 47.5% | 20.4% | 18.4% |
| Diluted EPS | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 |
| EBITDA | $4.11B | $4.53B | $4.47B | $5.08B | $9.23B | $3.81B | $2.42B | $2.68B | $2.23B | $1.44B |
| Operating cash flow | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B | $2.62B | $2.43B | $2.20B | $1.31B | $1.49B |
| Free cash flow | $4.08B | $3.66B | $3.88B | $4.42B | $6.53B | $2.00B | $2.00B | $1.81B | $1.03B | $974.0M |
| Diluted shares | 108.6M | 115.1M | 113.7M | 113.5M | 112.2M | 115.1M | 114.6M | 114.8M | 115.9M | 116.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.12B | $2.49B | $2.73B | $3.11B | $2.89B | $2.19B |
| Short-term investments | $5.49B | $6.52B | $8.11B | $4.64B | $2.81B | $1.39B |
| Total debt | $2.71B | $2.70B | $2.70B | $2.70B | $2.70B | $2.70B |
| Total assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B |
| Total liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B | $6.14B |
| Shareholders' equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B | $11.03B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology